重型COVID-19患者血浆介质导致肺内皮屏障衰竭
约20%的有症状SARS-CoV-2感染者进展为重型COVID-19并符合ARDS的低氧血症标准。重型COVID-19以CT磨玻璃影和尸检弥漫性肺泡损伤为特征,提示通透性肺水肿驱动呼吸衰竭,尸检显示肺内皮严重损伤。本文报告了一种筛选血浆介质及屏障稳定化合物治疗潜力的平台。
要点
- 约20%有症状SARS-CoV-2感染者进展为重型COVID-19并符合ARDS标准。
- 重型COVID-19特征为CT磨玻璃影和尸检弥漫性肺泡损伤。
- 尸检显示重型COVID-19死者存在严重肺内皮损伤。
核心结论
- COVID-19患者血浆可诱导肺微血管屏障衰竭,且随疾病严重程度增加。
研究设计与样本
- 本文报告了一种筛选血浆介质及屏障稳定化合物治疗潜力的平台。
主要发现
- COVID-19患者血浆诱导肺微血管屏障衰竭,并随疾病严重程度加重。
- 约20%有症状SARS-CoV-2感染者进展为重型COVID-19,出现符合ARDS标准的严重低氧血症。
- 重型COVID-19以CT磨玻璃影和尸检弥漫性肺泡损伤为特征。
- 尸检显示重型COVID-19死者存在严重肺内皮损伤。
关键数值与推荐
- 重型COVID-19定义为有症状SARS-CoV-2感染者出现符合ARDS标准的严重低氧血症。
临床怎么用
- 可关注血浆介质作为肺内皮屏障衰竭的潜在干预靶点。
- 屏障稳定化合物可能对重型COVID-19肺水肿具有治疗潜力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The plasma of COVID-19 patients induces pulmonary microvascular barrier failure, which increases with disease severity. Here, a screening platform to test for plasma mediators and the therapeutic potential of barrier stabilising compounds is reported. https://bit.ly/3k4C0tB Approximately 20% of symptomatic patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection progress to severe coronavirus disease 2019 (COVID-19) with critical hypoxaemia fulfilling the criteria of acute respiratory distress syndrome (ARDS). Consistent with the classic features of ARDS, severe COVID-19 is characterised by ground glass opacities on computed tomography imaging and diffuse alveolar damage post mortem [1], suggesting permeability-type lung oedema as driver of respiratory failure. Consistent with this concept, autopsy findings show severe lung endothelial injury in patients who succumbed to COVID-19 [2].
引用
- Michalick L, Weidenfeld S, Grimmer B, et al. Plasma mediators in patients with severe COVID-19 cause lung endothelial barrier failure. Eur Respir J. 2021. PMID: 33154030. doi:10.1183/13993003.02384-2020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。